Trial Profile
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 7-Day Safety and Tolerability Study of Denufosol Tetrasodium Inhalation Solution Administered Via PARI LC Star in Patients 2 to 4 Years of Age With Cystic Fibrosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Denufosol (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Acronyms REACH-1
- Sponsors Merck Sharp & Dohme
- 30 May 2014 New trial record